Methodological Validation and Inter-Laboratory Comparison of Microneutralization Assay for Detecting Anti-AAV9 Neutralizing Antibody in Human
Viruses · 24.09.2024 · 16 (10) · 1512
DOI: 10.3390/v16101512 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, online erschienen am 24.09.2024. Verfasst von Shuangqing Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Genecradle Therapeutics Inc., Beijing 100176, China. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Dependovirus, Neutralization Tests, Antibodies, Viral. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National High-Level Hospital Clinical Research Funding, Beijing E-town Cooperation & Development Foundation.
Abstract (Originalsprache)
Anti-AAV neutralizing Abs (NAbs) titer is usually measured by cell-based microneutralization (MN) assay and is crucial for patient screening in AAV-based gene therapy clinical trials. However, achieving uniform operation and comparable results among different laboratories remains challenging. Here, we established a standardized MN assay for anti-AAV9 NAbs in human sera or plasma and transferred the method to the other two research teams. Then, we validated its parameters and tested a set of eight human samples in blind across all laboratories. The end-point titer, defined by a transduction inhibition of 50% (IC50), was calculated using curve-fit modelling. A mouse neutralizing monoclonal antibody in human negative serum was used for system quality control (QC), requiring inter-assay titer variation of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genecradle Therapeutics Inc., Beijing 100176, China.
- Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigati…
- Beijing FivePlus Gene Technology Co., Ltd., Beijing 102629, China.
- Beijing Joinn Laboratory Co., Ltd., Beijing 100176, China.
- State Key Laboratory of Complex Sever and Rare Diseases, Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
ORCID-Profile: Wenhao Ma, Xiaohong Han
Förderung
- CAMS Innovation Fund for Medical Sciences
- National High-Level Hospital Clinical Research Funding
- Beijing E-town Cooperation & Development Foundation
- Beijing E-town Cooperation & Development Foundation
Zitieren
APA
Yu, S., Zhao, Q., Zhang, C., Fu, D., Zhu, X., Zhou, J., Ma, W., Dong, Z., Zhai, X., Jiang, L., Han, X., Zhang, S., Wu, X., & Dong, X. (2024). Methodological Validation and Inter-Laboratory Comparison of Microneutralization Assay for Detecting Anti-AAV9 Neutralizing Antibody in Human. Viruses, 16(10), 1512. https://doi.org/10.3390/v16101512
Vancouver
Yu S, Zhao Q, Zhang C, Fu D, Zhu X, Zhou J, et al. Methodological Validation and Inter-Laboratory Comparison of Microneutralization Assay for Detecting Anti-AAV9 Neutralizing Antibody in Human. Viruses. 2024;16(10):1512. doi:10.3390/v16101512
BibTeX
@article{Yu2024,
author = {Yu, Shuangqing and Zhao, Qian and Zhang, Cengceng and Fu, Diyi and Zhu, Xueyang and Zhou, Jianfang and Ma, Wenhao and Dong, Zheyue and Zhai, Xiaoliang and Jiang, Lijie and Han, Xiaohong and Zhang, Shuyang and Wu, Xiaobing and Dong, Xiaoyan},
title = {Methodological Validation and Inter-Laboratory Comparison of Microneutralization Assay for Detecting Anti-AAV9 Neutralizing Antibody in Human},
journal = {Viruses},
year = {2024},
volume = {16},
number = {10},
pages = {1512},
doi = {10.3390/v16101512}
}
EUVIMED